Format

Send to

Choose Destination

See 1 citation found by title matching your search:

JACC Cardiovasc Interv. 2015 Aug 17;8(9):1229-1234. doi: 10.1016/j.jcin.2015.04.016.

A Prospective, Multicenter Study of a Novel Mesh-Covered Carotid Stent: The CGuard CARENET Trial (Carotid Embolic Protection Using MicroNet).

Author information

1
Medical Care Center, Hamburg University Cardiovascular Center, Hamburg, Germany. Electronic address: Schofer@herz-hh.de.
2
Jagiellonian University Department of Cardiac and Vascular Diseases, John Paul II Hospital, Krakow, Poland.
3
Medical Care Center, Hamburg University Cardiovascular Center, Hamburg, Germany.
4
Augusta Hospital, Dusseldorf, Germany.
5
Jagiellonian University Department of Cardiac and Vascular Diseases, John Paul II Hospital, Krakow, Poland; Krakow Cardiovascular Research Institute, Krakow, Poland.
6
CardioVascular Center, Frankfurt, Germany.

Abstract

OBJECTIVES:

This study sought to evaluate the feasibility of the CGuard Carotid Embolic Protective Stent system-a novel thin strut nitinol stent combined with a polyethylene terephthalate mesh covering designed to prevent embolic events from the target lesion in the treatment of carotid artery lesions in consecutive patients suitable for carotid artery stenting.

BACKGROUND:

The risk of cerebral embolization persists throughout the carotid artery stenting procedure and remains during the stent healing period.

METHODS:

A total of 30 consecutive patients (age 71.6 ± 7.6 years, 63% male) meeting the conventional carotid artery stenting inclusion criteria were enrolled in 4 centers in Germany and Poland.

RESULTS:

The primary combined endpoint was the procedure success of the CGuard system and the number and volume of new lesions on the ipsilateral side assessed by diffusion-weighted magnetic resonance imaging at 48 h post-procedure and at 30 days. The secondary endpoint was 30-day major adverse cardiac or cerebrovascular events (death, stroke, or myocardial infarction). Protection devices were used in all procedures. Procedure success was 100%, with 0% procedural complications. The 30-day major adverse cardiac or cerebrovascular events rate was 0%. New ipsilateral ischemic lesions at 48 h occurred in 37.0% of patients and the average lesion volume was 0.039 ± 0.08 cm(3). The 30-day diffusion-weighted magnetic resonance imaging showed complete resolution of all but 1 periprocedural lesion and only 1 new minor (0.116 cm(3)) lesion in relation to the 48-h scan.

CONCLUSIONS:

The use of the CGuard system in patients undergoing carotid artery stenting is feasible. In addition, the benefit of using CGuard may extend throughout the stent healing period.

KEYWORDS:

carotid artery stenting; diffusion-weighted magnetic resonance imaging; embolic protection; mesh stent

Comment in

PMID:
26292586
DOI:
10.1016/j.jcin.2015.04.016
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center